Currently, there are 307.92M common shares owned by the public and among those 297.53M shares have been available to trade.
The company’s stock has a 5-day price change of -17.69% and -36.58% over the past three months. FOLD shares are trading -34.29% year to date (YTD), with the 12-month market performance down to -40.65% lower. It has a 12-month low price of $6.20 and touched a high of $12.65 over the same period. FOLD has an average intraday trading volume of 3.39 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.08%, -22.40%, and -36.83% respectively.
Institutional ownership of Amicus Therapeutics Inc (NASDAQ: FOLD) shares accounts for 97.46% of the company’s 307.92M shares outstanding.
It has a market capitalization of $1.91B and a beta (3y monthly) value of 0.62. The earnings-per-share (ttm) stands at -$0.09. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.46% over the week and 5.64% over the month.
Analysts forecast that Amicus Therapeutics Inc (FOLD) will achieve an EPS of 0.01 for the current quarter, 0.12 for the next quarter and 0.78 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.03 while analysts give the company a high EPS estimate of -0.03. Comparatively, EPS for the current quarter was 0.06 a year ago. Earnings per share for the fiscal year are expected to increase by 51.94%, and 398.57% over the next financial year.
Looking at the support for the FOLD, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on December 13, 2024, with the firm’s price target at $17-$12. Jefferies coverage for the Amicus Therapeutics Inc (FOLD) stock in a research note released on September 06, 2024 offered a Buy rating with a price target of $18. Wells Fargo was of a view on May 30, 2024 that the stock is Overweight, while Guggenheim gave the stock Buy rating on May 14, 2024, issuing a price target of $13. Morgan Stanley on their part issued Overweight rating on December 19, 2023.
